Gossamer Bio
gossamerbio.com
Actively hiring
Oncology Therapeutics
Drug Discovery
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Visa sponsorship
1 ▼ 67%
H-1B filings in 12 months
$223k
Median offered salary
1
Open roles in United States
Who they sponsor
Medical and health services managers
1
In the register as Gossamer Bio Services, Inc., San Diego, CA
Other sponsors in the same field
Genentech 188 filingsBlueprint Medicines 9 filings
Obsidian Therapeutics 6 filings
Montai Therapeutics 4 filings
See 1 open role Alert me
US Department of Labor · latest filing Aug 1, 2025 · Visa details by country
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Gossamer Bio Files First NDA for Seralutinib PAH Drug
Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension
Read more
Report
Gossamer Bio, Inc. Submits New Drug Application to U.S. Fda for Seralutinib for Treatment of Pulmonary Arterial Hypertension
Read more
Report
Gossamer Bio (NASDAQ: GOSS) Schedules October 27 Vote on Warrants and Preferred Stock Conversion
Read more
Report
Gossamer Bio Executes Reverse Stock Split and Share Reduction
Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Gossamer Bio Stock Falls 6% After 1-For-80 Reverse Stock Split
Gossamer Bio, Inc. (GOSS) is down 6.14 percent, losing $0.70 to $10.69 on Friday. The move comes after the clinical-stage biopharmaceutical company completed its previously announced 1-for-80 reverse stock split, effective at 11:59 p.
Read more
Report
Comparative and combined effects of seralutinib and nintedanib suggest synergistic anti-fibrotic and anti-inflammatory activity in IPF patient-derived lung models
The post Comparative and combined effects of seralutinib and nintedanib suggest synergistic anti-fibrotic and anti-inflammatory activity in IPF patient-derived lung models appeared first on Gossamer Bio.
Read more
Report
Exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study
The post Exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study appeared first on Gossamer Bio.
Read more
Report
Targeted genetic profiling of PAH-predisposing genes and exploratory seralutinib response by genotype in the phase 3 PROSERA study
The post Targeted genetic profiling of PAH-predisposing genes and exploratory seralutinib response by genotype in the phase 3 PROSERA study appeared first on Gossamer Bio.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Gossamer Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
43/100
Developer tools
Microsoft Excel
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$192k
Typical range
$192k
Open positions
1
1
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $192k | $192k |
Highest paying role
Senior Manager, SEC Reporting & Technical Accounting
$192k
Normalized to USD per year
People
Faheem Hasnain
Executive Officer, Director
Sheila Gujrathi M.D.
Executive Officer, Director
Christian Waage
Executive Officer
Jill Howe
Executive Officer
Bryan Giraudo
Executive Officer
Laura Carter Ph.D.
Executive Officer
Caryn Peterson
Executive Officer
Richard Aranda M.D.
Executive Officer
Robert Smith
Executive Officer
Richard Lim
Director
Otello Stampacchia Ph.D.
Director
Robert Nelsen
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~4 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
100% ▼
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
2
Busiest office
San Diego
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
San Diego
United States
HQ
Sponsorship Disclosure
2 open roles 1 posted in 90 days 50-200 est. staff $192k Avg Salary
hires for Finance, Early Careers
Suite 120, San Diego, CA 92121
Dublin
Ireland
Regional office
Dublin, Ireland
Financials
Total raised
$632.6M
Latest round
Venture - Series Unknown
Funding rounds
4